In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer (Q45879149)

17 December 2017

title

In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer (English)

1 reference

17 December 2017

0 references

Sunil Sudarshan

1

1 reference

17 December 2017

David H Holman

2

1 reference

17 December 2017

Marc L Hyer

3

1 reference

17 December 2017

Christina Voelkel-Johnson

4

1 reference

17 December 2017

Jian-Yun Dong

5

1 reference

17 December 2017

James S Norris

6

1 reference

17 December 2017

publication date

1 January 2005

1 reference

17 December 2017

number of pages

7

1 reference

inferred from page(s)

published in

Cancer Gene Therapy

1 reference

17 December 2017

volume

12

1 reference

17 December 2017

issue

1

1 reference

17 December 2017

page(s)

12-18

1 reference

17 December 2017

The treated natural history of high risk superficial bladder cancer: 15-year outcome

cites work

1 reference

https://api.crossref.org/works/10.1038/SJ.CGT.7700746

Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.CGT.7700746

Membrane Fas Ligand Kills Human Peripheral Blood T Lymphocytes, and Soluble Fas Ligand Blocks the Killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.CGT.7700746

Purification and characterization of the Fas-ligand that induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.CGT.7700746

A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.CGT.7700746

Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.CGT.7700746

Monoclonal antibody-mediated tumor regression by induction of apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.CGT.7700746

Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.CGT.7700746

Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.CGT.7700746

Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.CGT.7700746

Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.CGT.7700746

Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.CGT.7700746

An induced proximity model for caspase-8 activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.CGT.7700746

The mitochondrial apoptosome: a killer unleashed by the cytochrome seas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.CGT.7700746

Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.CGT.7700746

Integrin alpha3beta1 is an alternative cellular receptor for adenovirus serotype 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.CGT.7700746

Preferential gene transfer to BBN-induced rat bladder tumor by simple instillation of adenoviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.CGT.7700746

Intravesical therapy for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.CGT.7700746

Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.CGT.7700746

Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.CGT.7700746

7 January 2021

inferred from DOI database lookup

A human cell line selected for resistance to adenovirus infection has reduced levels of the virus receptor.

1 reference

https://api.crossref.org/works/10.1038/SJ.CGT.7700746

7 January 2021

inferred from DOI database lookup

Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity

1 reference

https://api.crossref.org/works/10.1038/SJ.CGT.7700746

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.CGT.7700746

1 reference

17 December 2017

Dimensions Publication ID

1018649578

0 references

1 reference

17 December 2017